FDA Grants Fast Track Designation to Pharnext’s PXT3003 for CMT1A
News
Pharnext‘s PXT3003 was granted fast track designation for Charcot-Marie-Tooth disease type 1A (CMT1A) by the U.S. Food and Drug Administration, the company announced. “We are pleased to receive Fast Track designation for ... Read more